Briefing
Post-surgical ctDNA as a prognostic biomarker for relapse of resected cholangiocarcinoma.
Single-institution retrospective study of 48 patients with resected cholangiocarcinoma (2020–2025): 26 (54.2%) relapsed, and median follow-up was 18.3 months. A commercial tumor-informed ctDNA assay was compared with CA19-9 in a postoperative window (under 90 days) and a surveillance window (90 days or later). ctDNA positivity in both windows was associated with worse median disease-free survival; CA19-9 was not. For relapse at any time, postoperative sensitivity was 41.7% and specificity 85.7%, and surveillance sensitivity was 60.0% and specificity 90.9%. At a 1-year landmark using ctDNA drawn under 90 days, sensitivity was 83.3% and specificity 90.0%. Median lead time was 34 days (IQR 26–132), with a maximum of 292 days. Performance was better without perineural or lymphovascular invasion, and ctDNA was most often positive with extrahepatic metastases (10 of 13, 76.9%). The authors call ctDNA a specific prognostic biomarker that outperforms CA19-9, and say a negative result should be interpreted cautiously because sensitivity is modest.
The Oncologist (opens in a new tab)PubMed 43053293 (opens in a new tab)DOI 10.1093/oncolo/oyag455 (opens in a new tab)